Explore

Trendline Trendline
Gossamer Bio Faces Securities Class Action After Phase 3 Trial Failure Causes Stock Plunge

Gossamer Bio Faces Securities Class Action After Phase 3 Trial Failure Causes Stock Plunge

Gossamer Bio Faces Securities Class Action After Phase 3 Trial Failure Causes Stock Plunge
Trendline Trendline
Gossamer Bio Faces Securities Class Action Following 80% Stock Drop After Trial Failure

Gossamer Bio Faces Securities Class Action Following 80% Stock Drop After Trial Failure

Gossamer Bio Faces Securities Class Action Following 80% Stock Drop After Trial Failure
Trendline Trendline
Immutep Faces Securities Class Action as Trial Discontinuation Impacts Investors

Immutep Faces Securities Class Action as Trial Discontinuation Impacts Investors

Immutep Faces Securities Class Action as Trial Discontinuation Impacts Investors
Trendline Trendline
ImmunityBio Faces Securities Class Action Over Misleading Statements

ImmunityBio Faces Securities Class Action Over Misleading Statements

ImmunityBio Faces Securities Class Action Over Misleading Statements
Trendline Trendline
Faruqi Faruqi Reminds Gossamer Bio Investors of Class Action Deadline

Faruqi Faruqi Reminds Gossamer Bio Investors of Class Action Deadline

Faruqi Faruqi Reminds Gossamer Bio Investors of Class Action Deadline
Trendline Trendline
Parabilis Files for IPO Following $2.3 Billion Collaboration with Regeneron

Parabilis Files for IPO Following $2.3 Billion Collaboration with Regeneron

Parabilis Files for IPO Following $2.3 Billion Collaboration with Regeneron
Trendline Trendline
ImmunityBio Faces Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge

ImmunityBio Faces Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge

ImmunityBio Faces Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge
Trendline Trendline
Rosen Law Firm Investigates TruBridge for Securities Class Action Over Financial Reporting Errors

Rosen Law Firm Investigates TruBridge for Securities Class Action Over Financial Reporting Errors

Rosen Law Firm Investigates TruBridge for Securities Class Action Over Financial Reporting Errors
Trendline Trendline
Biogen and Denali Halt Development of Parkinson's Drug After Trial Failure

Biogen and Denali Halt Development of Parkinson's Drug After Trial Failure

Biogen and Denali Halt Development of Parkinson's Drug After Trial Failure
Trendline Trendline
Rosen Law Firm Urges Gossamer Bio Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Gossamer Bio Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Gossamer Bio Investors to Act Before Class Action Deadline
Trendline Trendline
BioMarin Pharmaceutical Stock Rises Following Positive Drug Trial Results

BioMarin Pharmaceutical Stock Rises Following Positive Drug Trial Results

BioMarin Pharmaceutical Stock Rises Following Positive Drug Trial Results
Trendline Trendline
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments